Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Plant-based fats outperform dairy fats in reducing heart disease and diabetes risks

A recent study confirms that replacing saturated fats from dairy with plant-based unsaturated fats significantly reduces cardiometabolic risks. The findings call for further validation in diverse populations.

2 Sep 2024

Clonal hematopoiesis drives femoral atherosclerosis in middle-aged adults

Researchers reveal that clonal hematopoiesis (CH) significantly increases the risk of developing femoral atherosclerosis, suggesting a unidirectional relationship independent of traditional cardiovascular risk factors.

2 Sep 2024

Wearable heart monitor for AF screening increases diagnoses but not stroke prevention

Screening for atrial fibrillation (AF) using a wearable heart monitor for 2 weeks can identify older adults with this potentially dangerous abnormal heart rhythm, but does not prevent subsequent strokes, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug - 2 Sept).

2 Sep 2024

Different types and sources of carbohydrate found to be protective against gout

The study found that carbohydrates prevent gout, whereas free sugars have the opposite impact.

2 Sep 2024

Fermented lingonberry juice shown to reduce inflammation and support gut health in IBD

Fermented lingonberry juice may help manage inflammatory bowel disease (IBD) by modulating both the oral and gut microbiomes, reducing inflammation, and promoting beneficial bacteria.

2 Sep 2024

Study finds higher heart attack risk days after cold exposure

Hospital admissions for heart attacks increase after exposure to lower air temperature and cold spells, according to a study published today in JACC, the flagship journal of the American College of Cardiology, and presented at the European Society of Cardiology (ESC) Congress 2024.

1 Sep 2024

Rising resting heart rate over the years linked to shorter lifespan, study show

Study finds that increases in resting heart rate over time significantly raise mortality risk, underscoring heart rate as a key factor in lifespan determination.

1 Sep 2024

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

1 Sep 2024

Study links blood markers to long-term cardiovascular risk in women

Research supported by the National Institutes of Health has found that measuring two types of fat in the bloodstream along with C-reactive protein (CRP), a marker of inflammation, can predict a woman's risk for cardiovascular disease decades later.

1 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024

Low-dose triple-pill combination outperforms standard care for blood pressure control in Nigerian adults

A low-dose triple single-pill combination-based protocol achieved better blood pressure (BP) control than a standard-care protocol in Black African Nigerian adults with uncontrolled hypertension, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Semaglutide cuts death rates from cardiovascular disease and COVID-19

Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, finds.

30 Aug 2024

Clonal hematopoiesis identified as new risk factor for atherosclerosis

To the known risk factors for cardiovascular disease-;high blood pressure, high cholesterol, diabetes, overweight and obesity, smoking, and physical inactivity-;a new one has to be added: clonal hematopoiesis.

30 Aug 2024

Semaglutide's impact on cardiovascular health expands beyond weight loss

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

New ESC guidelines introduce intensive blood pressure targets and renal denervation recommendations

Updated ESC Guidelines on the management of elevated blood pressure and hypertension include a new elevated blood pressure category, more ambitious and intensive treatment targets, and, for the first time, recommendations on the use of renal denervation to treat various forms of hypertension.

30 Aug 2024

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

CBL identified as the most promising potential biomarker for aortic dissection

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Aortic dissection (AD) is a fatal cardiovascular disease for which the key involved genes are largely unknown.

29 Aug 2024

Low lipoprotein (a) levels do not cause type 2 diabetes, research shows

New research has shown that, contrary to some previous studies, low levels of lipoprotein (a) – a parcel of fats and protein in the blood – do not cause type 2 diabetes.

29 Aug 2024

Routine lipoprotein(a) testing recommended for all adults

Heart experts say that everyone should have their levels of lipoprotein (a) (Lp(a) measured routinely at least once in life, following research from one of the most populous EU countries, Poland, that shows how common high levels of Lp(a) are in the general population.

29 Aug 2024